Shots:
- The US FDA has approved Ebglyss to treat moderate-to-severe AD in adults & children (≥12yrs.) weighing 88 pounds (40kg). Lilly holds its exclusive rights outside the EU, while Almirall has licensed rights in the EU
- The approval was supported by P-III (ADvocate 1 & 2) studies of Ebglyss alone and P-III (ADhere) study of Ebglyss + topical corticosteroids in over 1000 adults & children (12-18yrs.) with mod. to sev. AD
- ADvocate 1 & 2 studies showed clear or almost-clear skin in 38% vs 12% (77% maintained it for 1yr. with QM dosing & 48% maintained it after switching to PBO) and 43% vs 12% had itch relief at 16wks. (85% maintained for 1yr. with QM dosing & 66% maintained it post switching to PBO)
Ref: PRNewswire | Image: Eli Lilly| Press Release
Related News:- Roche’s Tecentriq Hybreza Receives the US FDA’s Approval for Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
